09.01.14
ALPHAEON Corporation, Irvine, CA, has acquired Physician Recommended Nutriceuticals (PRN), a developer of specialty omega-3s and related products for dry eye and macular degeneration, based in Plymouth Meeting, PA, in a transaction worth up to $55 million.
“ALPHAEON’s acquisition of PRN brings together world renowned ophthalmologists and a premier physician recommended line of nutraceutical products that benefit patients,” said ALPHAEON CEO Robert Grant. “Over the past 5 years, PRN has established a strong leadership position in the rapidly growing field of evidence-based physician recommended and dispensed nutraceuticals, achieving consistently high double-digit growth over several years. We are very pleased to partner with such a quality organization and leadership team and look forward to maintaining their stand-alone operation just outside of Philadelphia, PA. This acquisition brings significant customer synergies to both organizations and is ideally aligned to ALPHAEON’s mission to provide best-in-class wellness related products to patients.”
PRN’s dry eye patent-pending formula has the highest bioavailable concentration per serving of purified omega-3 fatty acids and the optimal ratio of 3:1 EPA/DHA, according to the company. Studies have shown Dry Eye Omega Benefits addresses the inflammation leading to dry eye and improve the recovery time from refractive and cataract surgery. In a dry eye clinical study, 82% of patients who consumed PRN’s re-esterified triglyceride (rTG) omega-3 product for an eight-week period had a positive change in the composition of their meibum, a potential root cause of dry-eye syndrome.
“ALPHAEON’s acquisition of PRN brings together world renowned ophthalmologists and a premier physician recommended line of nutraceutical products that benefit patients,” said ALPHAEON CEO Robert Grant. “Over the past 5 years, PRN has established a strong leadership position in the rapidly growing field of evidence-based physician recommended and dispensed nutraceuticals, achieving consistently high double-digit growth over several years. We are very pleased to partner with such a quality organization and leadership team and look forward to maintaining their stand-alone operation just outside of Philadelphia, PA. This acquisition brings significant customer synergies to both organizations and is ideally aligned to ALPHAEON’s mission to provide best-in-class wellness related products to patients.”
PRN’s dry eye patent-pending formula has the highest bioavailable concentration per serving of purified omega-3 fatty acids and the optimal ratio of 3:1 EPA/DHA, according to the company. Studies have shown Dry Eye Omega Benefits addresses the inflammation leading to dry eye and improve the recovery time from refractive and cataract surgery. In a dry eye clinical study, 82% of patients who consumed PRN’s re-esterified triglyceride (rTG) omega-3 product for an eight-week period had a positive change in the composition of their meibum, a potential root cause of dry-eye syndrome.
